Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Actuate Therapeutics Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04239092CT.gov 9-ING-41 in Pediatric Patients With Refractory Malignancies. | — | Terminated | — | — | — |
NCT03709680CT.gov Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT01837862CT.gov A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | — | Completed | — | — | — |
NCT00879437CT.gov Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Intrinsic Pontine Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Actuate Therapeutics Inc. | P2 | BB · 65 |
| (+)-Vincristine | Julie Krystal | P2 | B |
| Etoposide | Theodore S. Johnson | P2 | B |
| Valproic Acid | University of Göttingen | P3 | B |
| Nogitecan | Actuate Therapeutics Inc. | P2 | B |
| Indoximod | Theodore S. Johnson | P2 | B |
| Everolimus | Nationwide Children's Hospital | P2 | B |
| Cyclophosphamide | Shenzhen Geno-Immune Medical Institute | P2 | B |
| Ribociclib | Nationwide Children's Hospital | P2 | B |
+33 more in the Diffuse Intrinsic Pontine Glioma cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Diffuse Intrinsic Pontine Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-diffuse-intrinsic-pontine-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →